The Biogen Q3 2026 results, released on 28 October 2026, show a company growing sales again while its profit measures fell sharply. Biogen reported total revenue of $2,804.1 million for the third quarter, up 11% from $2,534.7 million a year earlier, and said its growth portfolio rose 49%. It also nudged up the bottom of its full-year earnings guidance. But the headline needs context: non-GAAP earnings per share dropped to $2.62 from $4.81, the GAAP result was a loss, and the guidance range had been cut in July. This explainer sets out what changed, why, and what the company has not said.
Key takeaways from the Biogen Q3 2026 results
- Total revenue was $2,804.1 million, up 11% (10% at constant currency); product revenue was $2,088.7 million, up 13%.
- Non-GAAP diluted EPS was $2.62 against $4.81 a year earlier; GAAP diluted EPS was a loss of $0.14 per share.
- Both profit measures include about $284 million of acquired in-process R&D and related charges, mainly from the RayThera acquisition.
- Full-year non-GAAP EPS guidance now stands at $12.20 to $13.00, up from $12.00 to $13.00 in July but well below February’s $15.25 to $16.25.
- A key Phase 3 lupus readout for litifilimab is expected in the first half of December 2026.
The headline numbers in the Biogen Q3 2026 results
Revenue growth was broad enough to matter. Total revenue of $2,804.1 million compares with $2,534.7 million in the third quarter of 2025, which works out at about 10.6% by our own calculation, in line with the 11% the company reported. The company said the Growth Portfolio, which includes Leqembi, Skyclarys, Zurzuvae and the eye and rare-disease products, generated about $1.26 billion, up 49%, and made up roughly 63% of core pharmaceutical revenue. Chief executive Christopher Viehbacher said the quarter demonstrated that Biogen had returned to growth. That is the company’s characterisation; the figures above come from its own announcement, available on the Biogen investor relations site.
Why earnings fell in the Biogen Q3 2026 results despite higher sales
The difference between revenue and profit is largely about acquisition accounting and one-off charges. Non-GAAP net income was $391.4 million against $707.5 million a year earlier, and non-GAAP diluted EPS fell to $2.62 from $4.81, a decline of about 45% by our own calculation. On a GAAP basis the company posted a net loss of $20.6 million, or $0.14 per share, against a profit of $3.17 per share a year earlier. Biogen said both measures include $284 million of acquired in-process R&D, upfront and milestone expense, mainly tied to the RayThera acquisition. GAAP research and development spending was $574.0 million and selling, general and administrative expense was $752.0 million. The brief headline of rising revenue is accurate; it just does not describe the earnings picture on its own.
What “raised guidance” actually means in the Biogen Q3 2026 results
Guidance is where wording matters most. In February, Biogen guided to full-year non-GAAP EPS of $15.25 to $16.25. In July it cut that range to $12.00 to $13.00, citing roughly $3.00 of acquired R&D and similar charges and about $0.85 of dilution from the Apellis acquisition. In October, it moved the low end to $12.20, so the range is now $12.20 to $13.00. By our own calculation the midpoint rose from $12.50 to $12.60. The company also said Apellis dilution is now expected to be about $0.55 and acquired R&D charges about $3.20, which would leave underlying guidance of $15.95 to $16.75. So the range was raised at the bottom, after being lowered earlier in the year, and remains well under the February starting point.
Product performance behind the Biogen Q3 2026 results
- Leqembi: Biogen’s 50% share was $68.4 million, up 60%; global in-market sales recorded by partner Eisai were $202 million, up 67%.
- Skyclarys: $178.2 million, up 34%.
- Spinraza: $460.6 million, up 23%.
- Zurzuvae: $84.4 million, up 53%.
- Qalsody: $37.5 million, up 42%.
- Tysabri: $437.1 million, up 1%; Vumerity: $192.0 million, down 11%; multiple sclerosis product revenue overall $919.3 million, down 13%.
The Apellis effect in the Biogen Q3 2026 results
Biogen closed its acquisition of Apellis in May 2026, adding Syfovre, for geographic atrophy, and Empaveli. Syfovre contributed $191.3 million and Empaveli $51.5 million in the quarter. Prior-year figures for those products come from Apellis’s own filings, so year-on-year comparisons for the combined company should be read with care. Part of the reported growth therefore reflects acquired products and not only organic gains. The company has not broken out how much of the 11% revenue growth is acquired in the data we reviewed.
Balance sheet and cash in the Biogen Q3 2026 results
At 30 September, Biogen held about $1.3 billion in cash and about $7.7 billion of debt, which implies net debt of about $6.4 billion by our own calculation. Third-quarter operating cash flow was about $641 million and free cash flow about $600 million. Filings are available through the US Securities and Exchange Commission. Revenue is expected to grow by a mid-single-digit percentage for the year, with combined non-GAAP R&D and SG&A of about $4.95 billion.
Pipeline catalysts after the Biogen Q3 2026 results
Investors and clinicians will watch several readouts. Phase 3 topline data for litifilimab in systemic lupus erythematosus, the TOPAZ-1 and TOPAZ-2 studies, are expected in the first half of December 2026. Readouts for litifilimab in cutaneous lupus and for felzartamab are guided to the first half of 2027, and the Phase 3 zorevunersen study in Dravet syndrome to the third quarter of 2027. These are company-stated timings and can change.
Market context from Acumen Research and Consulting
Acumen Research and Consulting’s Biopharmaceutical Market report values the global market at USD 328 billion in 2021 and projects USD 853 billion by 2030, a CAGR of 11.3% for 2022 to 2030. It says North America held over 33% of the market in 2021 and that monoclonal antibodies accounted for about 32%. The report is broad and dated, so it frames the industry backdrop and says nothing specific about Biogen. See our Pharmaceutical coverage.
Timeline of the Biogen Q3 2026 results
- February 2026: full-year non-GAAP EPS guidance of $15.25 to $16.25.
- May 2026: Apellis acquisition closes.
- July 2026: guidance cut to $12.00 to $13.00.
- 28 October 2026: third-quarter results, guidance low end raised to $12.20.
- First half of December 2026: litifilimab lupus Phase 3 topline expected.
General background: GAAP versus non-GAAP
GAAP figures follow standard accounting rules. Non-GAAP figures adjust for items a company considers unusual, such as acquisition costs. Both are useful, and neither is a forecast. Comparing them shows how much of a result depends on one-off events.
Our analysis of the Biogen Q3 2026 results
In our assessment, the Biogen Q3 2026 results support the claim that revenue is growing again, helped by newer products and acquisitions, but they do not show earnings recovery. The raised low end of guidance is small and follows a cut. The next test is whether the growth portfolio continues to offset the decline in multiple sclerosis products.
What is not disclosed in the Biogen Q3 2026 results
- How much revenue growth came from acquired products.
- Detailed product-level profitability.
- The outcome of the lupus Phase 3 studies.
Risks and caveats
Company-reported figures have not been independently audited in this article. Pipeline timings can slip, and trial results can be negative. This article is news reporting and not investment advice.
What to watch next after the Biogen Q3 2026 results
- The December lupus topline results.
- Further Leqembi uptake figures from Eisai.
- Whether acquired R&D charges rise again.
Questions the Biogen Q3 2026 results leave open
How fast can newer drugs replace falling multiple sclerosis revenue? What will Apellis products contribute over a full year? Will further acquisitions add more one-off charges? The company’s announcement does not answer these, and we do not guess.
FAQ
Did revenue rise in the Biogen Q3 2026 results?
Yes. Total revenue was $2,804.1 million, up 11%.
Did Biogen raise guidance?
Only the low end, from $12.00 to $12.20, after cutting the range in July.
Did earnings per share rise?
No. Non-GAAP diluted EPS fell to $2.62 from $4.81 and GAAP EPS was a loss.
How we reported this: we relied on the company announcement, regulator filings and the Acumen Research and Consulting report cited above. Our calculations are labelled. Last updated 29 October 2026. This is news reporting and not advice.